NorthX Biologics, a leading Nordic biopharmaceutical Contract, Development and Manufacturing Organization (CDMO), announced a significant growth investment from Signet Healthcare Partners, a healthcare private equity firm with expertise in pharmaceutical services.
This strategic deal will enable NorthX Biologics to accelerate its expansion plans, including enhancing facilities, broadening service lines, and extending U.S. commercial reach.
NorthX Biologics offers a wide range of complex biologics manufacturing services, including recombinant proteins, viral vaccines and cell therapies. And it serves a global customer base of biopharmaceutical and biotech companies, from early development through commercial GMP manufacturing.
The funding was made through a new issue of shares.
Flerie remains the majority shareholder following the deal. The deal was not disclosed.
New board member: Following the deal, James Gale, Managing Director at Signet Healthcare Partners, will join the NorthX Biologics Board of Directors.
Advisors: Setterwalls served as legal advisor to NorthX Biologics. Advokatfirman Delphi and Sheppard, Mullin, Richter & Hampton served as legal advisors to Signet.
KEY QUOTES:
“We are delighted to welcome Signet Healthcare Partners as a shareholder. With their significant experience in pharma services, they are an excellent complement to NorthX Biologics and are well positioned to support our journey.”
Janet Hoogstraate, Chief Executive Officer of NorthX Biologics
“With Signet Healthcare Partners, we gain another strong owner who brings extensive experience in developing fast-growing biopharmaceutical companies. I look forward to welcoming James to the board and working together with Signet to continue the global expansion of NorthX Biologics.”
Thomas Eldered, Chairman of NorthX Biologics and Flerie
“We are excited to invest in NorthX Biologics to support its ambitious growth strategy. NorthX Biologics’ differentiated capabilities across microbial and mammalian manufacturing systems, nucleic acids, advanced therapies and aseptic fill-finish are a strong match with the evolving needs of the global biopharma market. Together with Flerie, as a significant shareholder in NorthX Biologics, we look forward to helping accelerate NorthX Biologics commercial strategy while supporting its broader global vision.”
James Gale, Managing Director at Signet Healthcare Partners
